A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Latest Information Update: 16 May 2025
At a glance
- Drugs Cemiplimab (Primary) ; Sarilumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 08 May 2025 Status changed from recruiting to active, no longer recruiting.
- 18 Aug 2023 Status changed from not yet recruiting to recruiting.
- 02 Aug 2023 Planned initiation date changed from 31 Jul 2023 to 31 Jul 2024.